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Abstract: Sarcopenia and sarcopenic obesity are currently considered major global threats for
health and well-being. However, there is a lack of adequate preclinical models for their study.
The present trial evaluated the suitability of aged swine by determining changes in adiposity, fatty
acids composition, antioxidant status and lipid peroxidation, development of metabolic disturbances
and structural changes in tissues and organs. Iberian sows with clinical evidence of aging-related
sarcopenia were fed a standard diet fulfilling their maintenance requirements or an obesogenic diet for
100 days. Aging and sarcopenia were related to increased lipid accumulation and cellular dysfunction
at both adipose tissue and non-adipose ectopic tissues (liver and pancreas). Obesity concomitant
to sarcopenia aggravates the condition by increasing visceral adiposity and causing dyslipidemia,
insulin resistance and lipotoxicity in non-adipose tissues. These results support that the Iberian swine
model represents certain features of sarcopenia and sarcopenic obesity in humans, paving the way
for future research on physiopathology of these conditions and possible therapeutic targets.
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1. Introduction
Sarcopenia is a syndrome characterized by loss of skeletal muscle mass and function [1], causing
negative health outcomes like functional decline and disability [2–4] and increased mortality [5]. This
may be further aggravated in case of obesity and increases in fat mass (sarcopenic obesity; [6]) which
increases mobility and disability problems [7]. Currently, around 20 and 30% of elderly women and
men, respectively, may have sarcopenic obesity [8]. Sarcopenic obesity is also related to metabolic
disturbances, like metabolic syndrome and type-2 diabetes [9]; it is, therefore, considered a major
global threat to health and well-being [10].
There are currently no drugs for the treatment of sarcopenia [7,11] and the recommended
therapeutic interventions are based on lifestyle changes [9], with limited effects and with difficult
implementation in elderly individuals with chronic diseases or different disabilities. Hence, there is
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a strong need for research efforts on pathogenesis and possible treatments. The results will contribute
to relevant improvements of individual life-quality and savings in health-care resources.
Almost all the available studies are observational (with their inherent constraints),
and interventional research is, therefore, necessary. Such research should be based on adequate
translational animal models as elegantly reviewed by Palus in 2017 [12]. Most of the interventional
trials on sarcopenia have been performed in rodents and have been based on induced acute muscle
atrophy. These models do not represent sarcopenia by ageing [9], which needs long time to be
achieved (around 20–24 months [13]). Moreover, the study of metabolic implications of sarcopenic
obesity in rodents is constrained by their marked differences in metabolic and endocrine pathways
with humans [14]. There is, consequently, a need for complementary preclinical animal models.
The use of non-rodent mammals is essential to develop more relevant and predictive models of human
disease. In this way, large animals have close similarities to humans in size and in many anatomical,
physiological and pathological features. Moreover, large animal models of human diseases can be
studied employing the same clinical approach used for human patients. In this sense, the pig has more
similar patho-physiological features to humans than rodents [15].
Pigs used for biomedical research can be either random- or purpose-bred. Pigs from random-bred
are typically farm animals (e.g., Landrace, Large White, Pietrain), where genetic selection is focused
on animal production parameters. Purpose-bred pigs for biomedical research originate from closed
colonies selected for a specific phenotype. The most commonly used swine breeds for research on
obesity and metabolic diseases are Göttingen, Yucatan and Ossabaw Island pigs. However, all these
breeds have a common ancestor: the Iberian pig.
The Iberian pig has an ancient origin, being traced back approximately to year 1000 Before Christ,
and has been traditionally reared under extensive free-range conditions, using natural resources like
pastures and acorns. Maintenance in semi-feral conditions has induced the pigs to develop an adaptive
mechanism to the environment, which is known as thrifty genotype and which was firstly described in
humans [16]. The thrifty genotype facilitates accommodation to seasonal cycles of feasting and famine
because the ability to store fat in excess during food abundance enables survival during periods of
scarcity. However, these individuals become obese in case of food-excess. Iberian pigs arise therefore
as good model for studies on obesity and associated morbidities, since they develop cardiovascular
and metabolic disorders in case of obesity, either during juvenile development [17] or adulthood [18].
The Iberian pig may be also useful for studies focused on sarcopenia, since the breed is reared
under extensive traditional systems which facilitates the finding of older animals than in the case of
breeds used for meat production under intensive management conditions (e.g., Landrace, Large-White,
Pietrain). Intensive animal production systems are associated to intense genetic and productive
selection and sows identified as having lower performance than the herd average are early culled,
as early as age as 3–4 year-old [19]. Conversely, genetic and productive demands are not so
strong in extensive traditional systems and culling is more related to either reproductive failures
or musculoskeletal and locomotive disorders associated to age (which are similar to those associated
with human sarcopenia).
Hence, the present study aimed to characterize a large-animal model for preclinical studies on
sarcopenia and sarcopenic obesity, based on the use of old Iberian sows with aging-related sarcopenia
and exposed or not to obesogenic diets. The validity of the models was assessed by determining
possible links among adiposity, fatty acids composition, antioxidant status and lipid peroxidation,
development of metabolic disturbances and structural changes in tissues and organs.
2. Results
2.1. Body-Weight and Adiposity
All the animals fed with the obesogenic diet showed a significant increase in body-weight
(123 ± 6.1 to 202.3 ± 4.9 kg, p < 0.0001) and adiposity (16.1 ± 2.4 to 45.6 ± 2.9 mm of back-fat depth,
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p < 0.0001) from Day 0 to 100 (Figure 1). The values in control sows were similar to the initial values
in obese sows (127.9 ± 4.0 kg and 19.3 ± 1.3 mm, respectively). The macroscopic findings during
necropsy indicated a severe intraabdominal fattening in obese sows, with large amounts of mesenteric
fat covering all viscerae and mesenteric tissues. However, intramuscular fat content was similar in
obese and non-obese sows (12.9 ± 1.1% vs. 12.8 ± 0.7%).
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polyunsaturated FA (PUFA), n-3 and n-6 PUFA (p < 0.005 for all). Visceral fat in obese sows also 
evidenced a higher MUFA content (p < 0.0001; Supplementary Table S3) and a lower content of 
PUFA, n-3 and n-6 PUFA (p < 0.0001 for all) than non-obese females. There were no differences at 
subcutaneous fat, but visceral fat of obese females showed higher ratios of MUFA/saturated FA 
(SFA) and C18:1/C18:0 (p < 0.05 for both). 
The analysis of the fatty acid composition in the longissimus dorsi showed major effects at the 
polar lipid fraction (Supplementary Table S4). Obese sows showed a higher MUFA content and a 
lower content of SFA and PUFA than the controls and, as a consequence, higher MUFA/SFA and 
C18:1/C18:0 ratios (p < 0.005 for all). The content of n-3 and n-6 PUFA were lower, with a higher 
Σn-6/Σn-3 ratio, in obese than in control sows (p < 0.005 for all). The effects from obesity were minor 
at the neutral fraction (Supplementary Table S5), with MUFA content being lower in obese than in 
control females (p < 0.01). 
2.3. Hepatic Architecture, Fatty Acid Composition and Function 
The total fat content in the liver was similar in control and obese groups (15.3 ± 0.2% vs. 14.5 ± 
0.4%). Histological evaluation of the liver (Figure 2) indicated lipid accumulation in all the obese and 
in 82.4% of the control sows, with degrees varying from mild (63.6% and 76.5%, respectively) to 
moderate (36.4% and 23.5%, respectively). Increased presence of lipocytes (also known as 
perisinusoidal fat-storing cells, stellate cells or Ito cells) was found in all the obese and in 88.2% of 
the control sows. There were no evidences of inflammation or fibrosis, but hydropic degeneration 
was observed in 23.5% of the controls and all the obese animals (p < 0.05). All the controls had mild 
Figure 1. Mean (±S.E.M.) values in body-weight (A) and back-fat depth (B) in control sows (white dot;
n = 17) and changes in such values over time after starting differential feeding with a diet enriched with
saturated fat in treated sows (black line and dots; n = 11). Asterisks (*) denote significant differences
between obese and non-obese sows (p < 0.05).
2.2. Fatty Acid Composition of Subcutaneous and Visceral Fat and Muscle
The composition of fatty acids (FA) was similar at the outer and inner layers of subcutaneous fat
(Supplementary Tables S1 and S2). Overall, when compared to non- bese sows, obese females showed
a hig er monounsaturated FA (MUFA) content (p < 0.05) and lower conte ts of polyu saturated
FA (PUFA), n-3 n n-6 P (p < 0.005 for all). Visceral fat in obese sows also evid nced a higher
MUFA co t nt (p < 0.0001; Supplementary Table S3) and a lowe content of PUFA, n-3 and -6 PUFA
(p < 0.0001 for all) than non-obese females. There were no differences at subcutaneous fat, but visceral
fat of obese females showed higher ratios of MUFA/saturated FA (SFA) and C18:1/C18:0 (p < 0.05
for both).
The analysis of the fatty acid composition in the longissimus dorsi showed major effects at the polar
lipid fraction (Supplementary Table S4). Obese sows showed a higher MUFA content and a lower
content of SFA and PUFA than the controls and, as a consequence, higher MUFA/SFA and C18:1/C18:0
ratios (p < 0.005 for all). The content of n-3 and n-6 PUFA were lower, with a higher Σn-6/Σn-3 ratio,
in obese than in control sows (p < 0.005 for all). The effects from obesity were minor at the neutral
fraction (Supplementary Table S5), with MUFA content being lower in obese than in control females
(p < 0.01).
2.3. Hepatic Architecture, Fatty Acid Composition and Function
The total fat content in the liver was similar in control and obese groups (15.3 ± 0.2% vs.
14.5 ± 0.4%). Histological evaluation of the liver (Figure 2) indicated lipid accumulation in all
the obes nd in 82.4% of the control sows, with degrees varying from mild (63.6% and 76.5%,
respectively) to moderate (36.4% and 23.5%, respec ively). Increased presence of lipocytes (also known
as perisinusoidal fat-storing c lls, st llat cells or Ito cells) was found in all the obese and in 88.2% of
the control sows. There were no evidences of inflammation or fibrosis, but hydropic degeneration
was observed in 23.5% of the controls and all the obese animals (p < 0.05). All the controls had mild
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degeneration, whilst the obese sows showed mild (27.3%), moderate (63.7%, p < 0.05) or even severe
degeneration (9.0%, p < 0.05).
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Figure 2. Histological images of liver and pancreas in obese sows. Upper pictures represent mild (A)
and moderate (B) infiltration of lipids, stained in red, in the liver (oil red-O, 400×) Bar 50 µm. Pictures
(C) and (D) of the liver represent mild and severe hydropic degeneration, respectively, whilst picture E
exemplifies increased presence of lipocytes or Ito cells indicated with arrows (hematoxylin-eosin HE,
400×) Bar 50 µm. Picture F represents infiltration of adipocytes with intracytoplasmic accumulation of
lipids, stained in red, in the pancreas (oil red-O, 100×) Bar 200 µm.
The major effects of obesity on fatty acids composition of t e liver, like in the muscle, were found
at the polar fraction (Supplem ntary Table S6), with high r MUFA/SFA, C18:1/C18:0 and Σn-6/Σn-3
ratios in the obese than in the control females (p < 0.0001 for all). The neutral fraction (Supplementary
Table S7) was characterized by a higher SFA content (p < 0.01) and a higher Σn-6/Σn-3 ratio (p < 0.0001)
in the obese animals.
The obese sows showed no major changes in the plasma biomarkers of liver function throughout
the study, excepting a significant increase in the concentrations of alkaline-phosphatase (56.5 ± 8.7
to 76.8 ± 10.1 IU/L, p < 0.05) and leucine-aminopeptidase (16.5 ± 1.9 to 21.4 ± 0.7 IU/L, p < 0.01).
Conversely, albumin concentration decreased over time (4.6 ± 0.1 to 4.1 ± 0.1 g/dL; p < 0.05), from
initial values similar to controls (4.7 ± 0.1 g/dL).
2.4. Plasma Lipid Profile
Plasma concentrations of triglycerides and cholesterol increased with time of treatment in the
obese group (p < 0.05; Figure 3), starting from values similar to those of control sows at Day 0.
The increase in total cholesterol was accompanied by a similar increase in low-density lipoproteins
cholesterol (LDL-c) levels (p < 0.01) but not in high-density lipoproteins cholesterol (HDL-c). Hence,
total cholesterol/HDL-c, LDL-c/HDL-c and atherogenic dyslipidemia ratios increased with time
(p < 0.05).
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Figure 3. Mean (±S.E.M.) plasma concentrations of triglycerides (A), cholesterol (B), HDL-c (C) and
LDL-c (D) in control sows (white bar; n = 17) and changes in such values over time after starting
differential feeding with a diet enriched with saturated fat in treated sows (black bars; n = 11). Asterisks
(*) denote significant differences between obese and non-obese sows (p < 0.05).
2.5. Plasma Antioxidant Cap city and Lipid Oxidation
The plasma antioxidant capacity (measured by F ; ferric reducing antioxidant power assay)
decreased in the obesogenic-diet group (fro 23.6 ± 2.7 at Day 0 to 16.9 ± 2.6 µ ol/mL at Day 100,
p < 0.05), starting from values similar to those of control animals (24.6 ± 4.0 µmol/mL). Concomitantly,
the values for total lipid oxidation (assessed as MDA; malondialdehyde) increased with time of
treatment in the obese group (from 10.7 ± 0.6 at Day 0 to 12.3 ± 0.3 µmol/mL at Day 100, p < 0.05),
starting from values similar to those of controls (10.6 ± 0.4 µmol/mL).
2.6. Pancreatic Architecture and Exocrine Function
Microscopic evaluation of the pancreas showed increased lipid accumulation in all the obese
sows. Around half of them showed severe infiltration (>66% of the cells; 45.5%), whilst the remaining
obese females showed moderate (34–66%; 27.3%) or mild infiltration (5–33%; 27.3%). Conversely,
lipid accumulation was found in 12 of the 17 controls (70.6%, p < 0.05), with degrees varying from
mild (47.1%) to moderate (23.5%), but not severe (p < 0.01 with obese sows). On the other hand,
no inflam ation, fibrosis or cellular injury were observed in any of the animals. Concomitantly,
the ssessment of plasma biomarkers of exocrine pancreatic function (lipase and amylase) showed no
major changes during the period of study.
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2.7. Pancreatic Endocrine Function and Insulin Resistance
Mean plasma concentrations of glucose and insulin, and HOMA-IR (Homeostatic Model
Assessment for Insulin Resistance) and HOMA-β (Homeostatic Model Assessment for β-cell function)
values were similar in controls and obese sows at Day 0. Afterwards, plasma glucose concentrations
in obese females were maintained by changes in insulin secretion throughout the period of study
(Figure 4). Insulin and HOMA-β index increased at Day 45 (p < 0.05 and p < 0.01, respectively)
and decreased again at Day 90 (p < 0.05 and p < 0.01, respectively). On the other hand, HOMA-IR
increased throughout the study (p < 0.05), evidencing insulin resistance (IR). Changes in insulin
secretion and glucose elimination were confirmed when analyzing the OGTTs (Oral Glucose Tolerance
Tests) performed during the study (Figure 5). In this way, the areas under the curve (AUCs) for glucose
and insulin were similar in control and treated sows at Day 0. Afterwards, at 45 and 90 days, AUCs for
glucose remained almost stable whilst AUCs for insulin increased 55.7% at Day 45 and 28.3% at Day
90 when compared to Day 0 (p < 0.01 and p < 0.05, respectively).
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Figure 4. Mean (±S.E.M.) plasma concentrations of glucose (A) and insulin (B) and values for
HOMA-IR and HOMA-β indexes (C and D, respectively) in control sows (white bar; n = 17) and
changes in such values over time after starting differential feeding with a diet enriched with saturated
fat in treated sows (black bars; n = 11). Asterisks (*) denote significant differences between obese and
non-obese sows (p < 0.05).
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Figure 5. Changes in plasma concentration of gl cose (continuous line with black circles) and insulin
(discontinuous line with white circles) over ti e after oral ad inistration of 2 g/kg live weight of
D-glucose in control sows (A; n = 17) and at 0 (B), 45 (C) and 90 days (D) after starting differential
feeding with a diet enriched with saturated fat in treated sows (n = 11). Areas under the Curve (AUCs)
for glucose and insulin were similar in control and treated sows at Day 0. AUCs for glucose remained
almost stable at 45 and 90 days but AUCs for insulin increased and were higher at both Day 45 and 90
than at Day 0 (p < 0.01 and p < 0.05, respectively).
3. Discussion
The present study characterizes aged Iberian pigs as a robust, amenable, and reliable translational
model for studies on sarcopenia and sarcopenic obesity. The model represents certain characteristics
of the hum n disease, since aging and sarcopeni were related to increased lipids accumulati n and
cellular dysfunction, not only at the adipose tissue but also at non-adi ose ectopic tissues (liver and
pancreas). The food-intake excess e ng to sarcopenic obesity worsened the co ition by ncreasing
visceral adiposity, dyslipidemia, insulin resistance and lipotoxicity in non-adipose tissues.
3.1. Sim larities of the Model with Human Sarc
In the pigs of the current study, aging was ch racterized, like in humans, by a significant reduction
in muscle mass; even 50% when compared to values obtained in younger adults. This sarcopenic state
was related to systemic dyslipidemia, insulin resistance (IR) and lipotoxicity in adipose tissue, liver
and pancreas (i.e., increased lipids accumulation and cellular dysfunction).
The comparison of lipid profiles in the current trial with data obtained in younger adult
pigs in previous studies [18] shows that plasma concentrations of triglycerides and total- and
LDL-cholesterol are significantly higher in aged than in young adult sows (around 50 vs. 25 mg/dL
for triglycerides, around 95 vs. 55 mg/dL for total cholesterol and around 55 vs. 25 mg/dL for
LDL-c). Conversely, increases in HDL-c were smaller (around 35 vs. 25 mg/dL). These data indicate
that in our model, ageing and sarcopenia induce a dyslipidemic profile similar to that described in
humans [20], resembling the so-called “lipid triad” (elevated triglycerides and LDL-c with normal
HDL-c; [21]). In consequence, aged sows have an increased atherogenic dyslipidemia ratio evidencing
cardiometabolic risk like human beings [22].
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In human medicine, elevated triglycerides in blood and tissues have been largely linked to
establishment of glucose intolerance and IR [23,24] and there is a well-known connection between
aging, sarcopenia and IR [20]. Concomitantly, in our sows, assessment of the glycemic index
showed that HOMA-IR and HOMA-β indexes are higher in aged and sarcopenic individuals than in
younger individuals.
The states of dyslipidemia and IR were accompanied by histological evidences of lipotoxicity in
the liver, with morphological alterations similar to those found in the early nonalcoholic fatty liver
disease (NAFLD) in humans. This finding indicates the main roles of IR and abnormal lipoprotein
metabolism in the pathogenesis of NAFLD in swine, like in humans [25]. Around 80–90% of the
non-obese sarcopenic sows evidenced lipids infiltration and increased presence of lipocytes (mostly
known as Ito cells). This finding supports the relationship between ageing and proliferation of Ito cells
previously described in human patients [26]. In 24% of our sows, the presence of ballooning injury,
if extrapolated to humans, would be indicative of predisposition to a later development of nonalcoholic
steatohepatitis (NASH) [25,27], a condition also known as lipotoxic liver disease [28]. The primary
role of Ito cells is the intracytoplasmic storage of fat and vitamin A [29]. However, damage of the liver
tissue is associated with proliferation of Ito cells, which plays an important role in the pathogenesis of
chronic liver disease [30] since the cells are subsequently transformed in myofibroblasts. Such a process
results in fibrogenesis and, in consequence, the normal hepatic tissue is replaced by fibrotic tissue in
advanced stages. There was no evidence of hepatic fibrosis in the current study, which indicates early
stages of liver disease. This assumption is reinforced by the lack of significant changes in most of the
enzymes used as markers of hepatic function that remained within physiological ranges during the
whole study [31,32].
Hence, the state of sarcopenia induced by aging in the Iberian sows of the present study represents
certain clinical and histological evidences of dyslipidemia, IR, lipotoxicity, NAFLD, and ultimately
prodrome of NASH, in human medicine.
3.2. Similarities of the Model with Human Sarcopenic Obesity
The obesogenic diet offered to sarcopenic sows affected body weight and adiposity very early
after starting the differentiated feeding, like previously described for younger pigs [18].
In the obese sows of the current study, increases in fat accretion were mainly observed at
subcutaneous and visceral compartments. In human medicine, it is well-known that aging-related
increases in visceral fat favor the development of dyslipidemia and IR [33]. In our model, increases in
visceral fat were similarly related to significant changes in the plasma lipids profile, which supports
that the lipidomic profile of swine is mainly determined by the visceral fat, as found in humans [33].
The increase in total cholesterol and LDL-c (indicating hyperlipidemia type-2) concurrently with
maintained low HDL-c levels found in our obese sarcopenic sows, if extrapolated to human medicine,
would be considered as indicative of type 2 of diabetes mellitus (T2DM; [34]. In our pigs, such diagnosis
was confirmed by the evidence of impaired glucose regulation throughout the study, with altered
β-cell function and IR. However, there were no changes in plasma glucose concentrations, like in the
first stages of the human disease [35], and our sows were able to counterbalance the prodrome of
T2DM at Day 90. These findings may be related to the short duration of the experiment and/or to
the high plasticity of the swine pancreas, in agreement with previous studies [36]. Hence, the data
obtained so far pave the way for further studies assessing IR in longer experimental trials.
An elegant revision of Mlinar and Marc [37] analyzes the different factors and steps in the link
between adiposity and IR. In brief, a triglyceride overload in non-adipose ectopic tissues occurs when
the capacity of the adipose tissue for storing lipids is exceeded. At the same time, the failure of the
vasculature to expand together with the adipocyte hypertrophy causes hypoxia of the adipose tissue
and, therefore, oxidative stress; in turn, oxidative stress is reinforced by an altered metabolism of the
non-adipose tissue. Systemic oxidative stress and steatosis in non-adipose tissues induce low-grade
inflammation. Finally, the concurrence of hypertriglyceridemia and ectopic lipid deposition, increased
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oxidative stress and inflammation trigger IR. All these factors described in humans were also found in
the obese sarcopenic sows of the current study.
Moreover, in our study, the assessment of fatty acid composition of subcutaneous and visceral fat,
where more than 95% were neutral lipids (triglycerides), offers outstanding information on its changes
during sarcopenic obesity. In brief, obesity increases MUFA content and decreases PUFA content
(specifically n-3 and n-6 PUFA) at both compartments, but also increases the ratios of MUFA/SFA and
C18:1/C18:0 in visceral fat (i.e., increases desaturation index and Stearoyl-CoA desaturase 1 activity;
SCD1). In humans, increased desaturation index and SCD1 activity have been related to metabolic
disorders, like alterations in lipogenesis and insulin regulation [23,38]. Similar results have been found
in the Iberian pig in previous studies [39,40].
In the present study, we observed major effects of obesity on fatty acid composition of the polar
fraction of cell membranes at non-adipose ectopic tissues (muscle and liver). Specifically, obese sows
showed higher MUFA/SFA, C18:1/C18:0 and Σn-6/Σn-3 ratios than control sows. The implications
of the two first ratios have been previously considered, but the changes in the Σn-6/Σn-3ratio also
indicate important metabolic impairments. In the skeletal muscle, the n-3 PUFA content of cellular
membranes plays a main role favoring the action of insulin; a high Σn-6/Σn-3ratio seems to be
deleterious to insulin sensitivity [41] and ultimately results in IR [42]. In the liver, the increase of
Σn-6/Σn-3ratio indicates also a pro-inflammatory state related to increased peripheral lipolysis and,
therefore, enlarged flux of fatty acids [43].
The histological evidence of lipotoxicity at the liver previously described in a high percentage of
the non-obese sarcopenic sows of the current study were also observed in the obese sows. All of them
(100%) evidenced lipid infiltration, increased presence of Ito cells and presence of ballooning injury
indicating nonalcoholic fatty liver disease (NAFLD) and later development of NASH. These data again
mimic results found in aged humans. The increasing prevalence of NAFLD with age was highlighted
in the Rotterdam study [44] while its relationship with sarcopenia has been reported, two years ago,
in the Korean Sarcopenic Obesity Study [45]. Further analysis of this last database highlighted that
this association is independent of obesity [46]. However, these studies are precluded by the inherent
limitation in conducting invasive experimentation in humans; hence, animal models for NAFLD are
necessary to better understand this pathogenesis. A recent comprehensive review of studies with
rodent models of NASH [47] states that the ideal model should encompass all the defining features
of the human condition (obesity, IR, steatohepatitis, and ultimately fibrosis). However, no single
murine model currently represents all subsets of human NASH. In this scenario, swine models have
an outstanding translational value.
In humans, the fatty liver is also closely associated with increased pancreatic fat content (a disorder
also known as nonalcoholic fatty pancreas disease, NAFPD) [48]. NAFPD is associated with visceral
obesity, dyslipidemia, IR and ultimately T2DM [49,50], which is similar to data from swine models [51].
A similar relationship was found in our current study, where pancreatic steatosis was severe in half of
the obese sows and moderate or mild in the remaining animals; conversely, only 70% of the controls
showed steatosis and most of them showed it to a mild degree. Moreover, all the obese sows showed
pancreatic lipomatosis, defined as fat accumulation around and within the pancreas. This is a condition
associated with aging and IR and known to worsen pancreatic dysfunction caused by steatosis [52].
Hence, these results also reinforce the translational value of our model for studies on the effect of
aging, obesity and IR on the development of NAFPD.
4. Materials and Methods
4.1. Ethics Statement
The experiment was performed in agreement with the Spanish Policy for Animal Protection
RD1201/05, which meets the European Union Directive 86/609. The experiment was specifically
assessed and approved by the Committee of Ethics in Animal Research of the National Institute
Int. J. Mol. Sci. 2018, 19, 823 10 of 15
of Agricultural and Food Research and Technology (INIA) (report CEEA 2012/012, 28 January
2012). The sows were housed at the animal facilities of INIA, which meet local, national and
European requirements.
4.2. Animals and Management
The experiment involved 28 Iberian sows (8–10 years-old) with established sarcopenia. Presence
of sarcopenia was assessed by ultrasonographic evaluation of muscle mass (cross-sectional diameter
of the longissimus dorsi), with a 5–8 MHz lineal-array probe (SonoSite Inc., Bothell, WA, USA), since
ultrasonography is accepted as a reliable method for evaluating muscle mass and sarcopenia [53].
Muscle diameter had a mean value of 21.9 ± 3.2 mm, which is 50% lower than values obtained in
adults (2 years-old; around 38–40 mm) and similar to data from young individuals (6 months-old;
around 20 mm) of the same breed reared at our facilities.
All the sows were fed, prior to the experimental procedure, with a standard diet (2.8%
of polyunsaturated fat and 3.08 Mcal/kg of metabolizable energy) fulfilling their maintenance
requirements (2.5 kg/animal/day). For 100 days, seventeen sows (control group) continued being
fed with the same diet and amount whilst 11 sows randomly chosen (obese group) were fed with
an obesogenic diet (6.8% of saturated fat and 3.36 Mcal/kg of metabolizable energy) for inducing
obesity [18]. Meal intake in the obese group was 4 kg/animal/day for the first 45 days and
5 kg/animal/day for the following 55 days.
4.3. Evaluation of Body Weight and Subcutaneous Adiposity
Changes in body-weight and subcutaneous fat-depth in the obese group were measured every
15 days, from Day 0 to 90, and finally at Day 100 together with the control group. Fat depth was
evaluated with the ultrasound probe previously described, at the right-side at 4 cm from the midline
and the head of the last rib.
4.4. Blood and Tissue Sampling
Plasma samples for assessment of glucose and lipids metabolism were drawn, after fasting,
at Days 0, 45, 90 and 100 in the obese group and at Day 100 in the control group and immediately
biobanked at −80 ◦C. Samples obtained at Days 0 and 100 in the obese group and at Day 100 in
the control group were also used to determine redox status. In addition, oral glucose tolerance tests
(OGTTs) were performed at Days 0, 45 and 90 in the obese and at Day 90 in the control sows by serial
blood samplings (0, 15, 30, 60, 90 and 120 min) after giving 2 g/kg live-weight of D-glucose by gavage
through a gastric tube.
At the end of the study (Day 100), a systematic necropsy was performed in all the animals,
assessing the macroscopic appearance of the organs. Immediately, two portions of subcutaneous
and visceral (perirenal) fat, muscle (longissimus dorsi), pancreas and left lobe of the liver were
collected in 2-mL cryotubes and biobanked at −80 ◦C for assessment of fatty acids and/or oil red-O
staining. A third portion of each tissue was fixed in 10% neutral-buffered-formalin and processed for
hematoxylin-eosin (HE).
4.5. Assessment of Plasma Lipid Profiles
Plasma concentrations of triglycerides, total cholesterol and high-density and low-density
lipoproteins cholesterol (HDL-c and LDL-c, respectively) were measured with a clinical chemistry
analyzer (Saturno 300-plus; Crony Instruments s.r.l., Rome, Italy). Plasma HDL-c ratio and LDL-c ratio
were calculated by dividing total cholesterol by HDL-c and LDL-c concentrations, respectively; plasma
LDL-c/HDL-c ratio was obtained by dividing LDL-c by HDL-c concentrations. Finally, the atherogenic
dyslipidemia ratio was calculated as log(triglycerides)/HDL-c.
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4.6. Assessment of Plasma Antioxidant Capacity and Lipid Peroxidation
Values for total antioxidant capacity were determined by FRAP (ferric reducing antioxidant power
assay) [54] whilst lipids oxidative damage was assessed by MDA (malondialdehyde) [55].
4.7. Assessment of Hepatic and Exocrine Pancreatic Function
Plasma concentrations of alanine-transaminase, albumin, alkaline-phosphatase, amylase,
aspartate-aminotransferase, total and direct bilirubin, creatinine, γ-glutamyl-transpeptidase,
leucine-aminopeptidase, lipase and urea were measured with the Saturno 300-plus analyzer (Crony
Instruments s.r.l., Rome, Italy).
4.8. Assessment of Glucose Metabolism and Endocrine Pancreatic Function
Plasma concentrations of glucose and insulin were measured, respectively, with the Saturno
300-plus analyzer and with a Porcine Insulin ELISA kit (Mercodia AB, Uppsala, Sweden; 0.26 IU/L
of assay sensitivity and 3.5% of intra-assay variation coefficient). Insulin sensitivity/resistance were
determined, concomitantly with data from OGTTs, throughout the study of the HOMA-IR index
[(FINS × FGLU)/22.5], whilst possible changes in β-cell function were assessed by the HOMA-β index
[(20 × FINS)/(FGLU − 3.5)]. FINS accounts for fasting plasma insulin concentration in U/L and FGLU
for fasting plasma glucose in mmol/L.
4.9. Histological Assessment of Liver and Pancreas
The stains of liver and pancreas tissue were examined by light microscopy and blindly scored for
the presence and severity of histological features indicating fat infiltration, steatosis, inflammation,
ballooning injury, fibrosis and vacuolization. Evaluation was based on the scoring developed by
Kleiner et al. [56], considering none (<5%), mild (5–33%), moderate (34–66%) and severe degree (>66%).
4.10. Evaluation of Fatty Acids Composition
Fatty acid composition was analysed in subcutaneous (after differentiation of outer and inner
layers) and visceral fat, longissimus dorsi muscle and liver. Fat was extracted using the Ball-mill
procedure [57] and gas-chromatography was used for identification and quantification of fatty acids
(FA) in total lipid extracts at subcutaneous and visceral fat, and separately for neutral (triacylglycerols
or triglycerides) and polar (phospolipids) lipids at muscle and liver [58]. Total saturated FA (SFA),
monounsaturated FA (MUFA) and polyunsaturated FA (PUFA) and total content of n-3 and n-6 PUFA
and their ratio (Σn-6/Σn-3) were calculated from individual FA percentages. Finally, the desaturation
index was obtained from the ratio MUFA/SFA and the activity of the stearoyl-CoA desaturase enzyme
1 (SCD1) was inferred from the proportions of oleic and stearic acids (C18:1n-9 and C18:0; product and
precursor of SCD1 activity, respectively).
4.11. Statistical Analysis
Effects of diet on body-weight, adiposity, fatty-acid composition, metabolic and
antioxidant/oxidative status were assessed by ANOVA for repeated measures (split-plot ANOVA),
whilst changes over time were determined by Pearson correlation procedures. Histological features were
assessed by one-way ANOVA or by a Kruskall–Wallis test if a Levene’s test showed non-homogeneous
variables; Duncan’s post-hoc test was performed to contrast the differences among groups. Statistical
analysis of results expressed as percentages was performed after arc-sine transformation of the values
for each individual percentage, while the response to OGTTs was compared after calculating the Area
under the Curve (AUC). All results were expressed as mean ± SEM and statistical significance was
accepted from p < 0.05.
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5. Conclusions
The present study shows that the Iberian swine model represents features of sarcopenia and
sarcopenic obesity in humans, paving the way for future research on physiopathology of the condition
and possible therapeutic targets. The strength of the model is increased by the availability and low-price
of aged individuals of this breed and the short time necessary for inducing obesity. The present study
was performed on female individuals, since availability of aged sows is higher than aged boars
and because management is easier in females, but sex-related effects may be studied on males in
further studies.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/19/3/823/s1.
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